DAX24.801 -0,5%Est505.979 -0,1%MSCI World4.343 -0,1%Top 10 Crypto8,6500 -0,7%Nas22.547 -0,2%Bitcoin58.301 +0,2%Euro1,1845 ±-0,0%Öl68,46 -0,2%Gold4.966 -0,5%
Beliebte Suche
DAX 40 Ölpreis Euro - Dollar Bitcoin - Euro Goldpreis
Meistgesucht
SAP 716460 Siemens 723610 Rheinmetall 703000 Deutsche Telekom 555750 Siemens Energy ENER6Y NVIDIA 918422 Amazon 906866 Lufthansa 823212 Microsoft 870747 DroneShield A2DMAA RENK RENK73 Deutsche Bank 514000 BASF BASF11 Allianz 840400 Mercedes-Benz Group (ex Daimler) 710000
Alle Aktien für 0 Euro (zzgl. Spreads) handeln mit finanzen.net zero. Hier informieren
Heute im Fokus
DAX schließt leichter -- Wall Street bleibt geschlossen -- Tesla: Staatsanwaltschaft ermittelt nach Anzeige -- VW, SAP, TUI, Rüstungsaktien, Siemens Energy, Bitcoin & Co, Alphabet, Palantir im Fokus
Top News
NVIDIA-Aktie außen vor: Morgan Stanley-Experten raten zu diesen neun KI-Titeln NVIDIA-Aktie außen vor: Morgan Stanley-Experten raten zu diesen neun KI-Titeln
BMW-Aktie: Vom Flugmotorenbauer zur globalen Premiummarke BMW-Aktie: Vom Flugmotorenbauer zur globalen Premiummarke
Suche...
Login
ODER

Neu auf finanzen.net?

Kostenfrei registrieren und Vorteile nutzen

Übersicht Wertpapierdepots Musterdepots Watchlists Meine News Newsletter Forum Trading Desk Apps Social Media Podcasts
Profil
Wer­bung
Unser ETF-Compass 2026: Die wichtigsten Trends für ETF-Anleger in diesem Jahr. Hier geht's zur Übersicht.

Simulations Plus Aktie

Kaufen
Verkaufen
10,30 EUR +0,20 EUR +1,98 %
FSE
12,27 USD +0,14 USD +1,15 %
BTT
Handle Aktien, ETFs, Derivate & Kryptos ohne Ordergebühren (zzgl. Spreads) beim ‘Kostensieger’ finanzen.net zero (Stiftung Warentest 12/2025)
Smartphone

Marktkap.209,05 Mio. EUR

Div. Rendite0,00%
WKN wurde kopiert
NEU
Handle jetzt direkt über finanzen.net mit Deinem Broker
Direkt handeln

WKN924294

ISIN wurde kopiert
NEU
Handle jetzt direkt über finanzen.net mit Deinem Broker
Direkt handeln

ISINUS8292141053

Symbol wurde kopiert
NEU
Handle jetzt direkt über finanzen.net mit Deinem Broker
Direkt handeln

SymbolSLP

Simulations Plus Aktien News

DatumMeistgelesen
PR NewswireINVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Simulations Plus, Inc. - SLP
PR NewswireRosen Law Firm Encourages Simulations Plus, Inc. Investors to Inquire About Securities Class Action Investigation - SLP
PR NewswireRosen Law Firm Encourages Simulations Plus, Inc. Investors to Inquire About Securities Class Action Investigation - SLP
PR NewswireRosen Law Firm Encourages Simulations Plus, Inc. Investors to Inquire About Securities Class Action Investigation - SLP
PR NewswireAppLovin, Robinhood Markets and Emcor Group Set to Join S&P 500; Others to Join S&P 100, S&P MidCap 400 and S&P SmallCap 600
PR NewswireINVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Simulations Plus, Inc. - SLP
PR NewswireRosen Law Firm Encourages Simulations Plus, Inc. Investors to Inquire About Securities Class Action Investigation - SLP
PR NewswireINVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Simulations Plus, Inc. - SLP
PR NewswireINVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Simulations Plus, Inc. - SLP
PR NewswireINVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Simulations Plus, Inc. - SLP
PR NewswireINVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Simulations Plus, Inc. - SLP
PR NewswireINVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Simulations Plus, Inc. - SLP
PR NewswireINVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Simulations Plus, Inc. - SLP
PR NewswireINVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Simulations Plus, Inc. - SLP
BusinesswireSimulations Plus Supported Development of Every FDA-Approved Drug in 2024
BusinesswireSimulations Plus Announces First Quarter Fiscal Year 2025 Earnings and Conference Call Date
BusinesswireSimulations Plus to Participate in the BTIG Digital Health Forum
BusinesswireSimulations Plus and the University of Connecticut Receive New FDA Grant to Expand Mechanistic Modeling Approaches for Long-Acting Injectables
BusinesswireSimulations Plus to Participate in the Stephens Annual Investment Conference
BusinesswireSimulations Plus and Partners Awarded New FDA Grant to Validate In Vitro-In Vivo Extrapolation Methods for Complex Formulations
BusinesswireSimulations Plus Announces Fourth Quarter and Fiscal Year 2024 Earnings and Conference Call Date
BusinesswireSimulations Plus and the University of Southern California Secure NIH Grant to Develop New AI Drug Discovery Offerings
BusinesswireSimulations Plus to Participate in the Morgan Stanley 22nd Annual Global Healthcare Conference
BusinesswireSimulations Plus Optimizes Business Unit Structure to Support Future Growth Following Recent Strategic Acquisitions
BusinesswireSimulations Plus Releases DILIsym® X
BusinesswireSimulations Plus Releases ADMET Predictor® Version 12
BusinesswireSimulations Plus to Participate in KeyBanc’s 25th Annual Technology Leadership Forum
BusinesswireSimulations Plus Announces New Research Project with the International Collaboration on Cosmetics Safety
BusinesswireSimulations Plus to Participate in the Morgan Stanley 3rd Annual Life Sciences AI Summit
BusinesswireSimulations Plus Announces Third Quarter Fiscal Year 2024 Earnings and Conference Call Date
BusinesswireSimulations Plus Acquires Pro-ficiency, Creating One-of-a-Kind Platform Spanning the Drug Development Continuum
BusinesswireSimulations Plus to Participate in 21st Annual Craig-Hallum Institutional Investor Conference
BusinesswireSimulations Plus Releases GastroPlus® X, The Next Generation PBPK/PBBM Modeling & Simulation Software
BusinesswireU.S. FDA Renews DILIsym® Software Licenses for 7th Year
BusinesswireSimulations Plus Announces Second Quarter Fiscal Year 2024 Earnings and Conference Call Date
BusinesswireSimulations Plus to Present at the KeyBanc Capital Markets Virtual Life Sciences & MedTech Investor Forum
BusinesswireSimulations Plus and the University of Bath Awarded New FDA Grant
BusinesswireSimulations Plus Extends Collaboration with Major Toxicology Research Agency
BusinesswireSimulations Plus Launches Corporate Development Initiative
BusinesswireSimulations Plus to Participate in Upcoming Healthcare Conferences

Simulations Plus News

Simulations Plus News: auf dieser Seite finden Sie alle Simulations Plus News und Nachrichten zur Simulations Plus Aktie. Dies beinhaltet die Agentur-Feeds auf finanzen.net, aber auch Simulations Plus News auf einer Vielzahl externer Seiten. Externe Links sind am entsprechenden Link-Symbol zu erkennen. Um Simulations Plus News auf externen Seiten zu lesen, folgen Sie einfach dem entsprechenden Link.